Central lymphatic irradiation to low dose for advanced nodular lymphoreticular tumors (non-Hodgkin's lymphoma).
Total central lymphatic irradiation (2500-3000 rads in 3 to 6 weeks) including the entire abdomen, the supradiaphragmatic nodal areas, and Waldeyer's ring is being investigated as a potentially curative approach to patients with Stage III disease. Twenty-two patients have been treated (24-month minimum observation). All evidence of disease has disappeared in every patient. Three patients have developed local recurrence; 2 of them received 2000 rads or less. Three patients had marginal recurrences, and 5 developed generalized disease involving viscera. Fourteen patients (64%) are alive and free of any evidence of disease from 24-90 months (median, 54 months). Absolute survival is 82% (18/22).
D000328:Adult; D000368:Aged; D003037:Cobalt Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000532:radiotherapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D014922:Wisconsin
D003037:Cobalt Radioisotopes